Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.84 EUR
Change Today -0.034 / -3.89%
Volume 0.0
UXI1 On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 4:28 AM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

cyclacel pharmaceuticals inc (UXI1) Snapshot

Open
€0.84
Previous Close
€0.88
Day High
€0.86
Day Low
€0.84
52 Week High
10/28/14 - €2.78
52 Week Low
02/3/15 - €0.48
Market Cap
28.9M
Average Volume 10 Days
9.2K
EPS TTM
--
Shares Outstanding
34.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CYCLACEL PHARMACEUTICALS INC (UXI1)

Related News

No related news articles were found.

cyclacel pharmaceuticals inc (UXI1) Related Businessweek News

No Related Businessweek News Found

cyclacel pharmaceuticals inc (UXI1) Details

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing small molecule drugs for the treatment of cancer and other serious diseases. The company’s oncology development programs include sapacitabine, an orally-available nucleoside analogue for the treatment of hematological cancers and solid tumors; and seliciclib, an orally-available cyclin dependent kinase (CDK) inhibitor that selectively inhibits a spectrum of enzyme targets comprising CDK2, -7 and -9, which are central to the process of cell division and cell cycle control. Its oncology development programs also comprise CYC065, an orally-available 2nd generation CDK-2, -5, and -9 inhibitor that helps in cancer cell growth, metastatic spread, and DNA damage repair; CYC140, an orally-available small molecule inhibitor of polo-like kinase 1; Sapacitabine + Seliciclib, which is in Phase I trials for the treatment of cancer; and Aurora kinase inhibitors, a serine/threonine protein kinases that focuses on cell division, or mitosis for the treatment of cancer. The company’s non-oncology programs comprise cell cycle inhibitors for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

18 Employees
Last Reported Date: 03/31/15
Founded in 1992

cyclacel pharmaceuticals inc (UXI1) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $530.6K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $324.4K
Chief Medical Officer and Vice President of C...
Total Annual Compensation: $348.4K
Compensation as of Fiscal Year 2014.

cyclacel pharmaceuticals inc (UXI1) Key Developments

Cyclacel Pharmaceuticals, Inc. Announces Presentation of Preclinical Data of CYC065

Cyclacel Pharmaceuticals, Inc. announced the presentation of preclinical data demonstrating therapeutic potential of CYC065, the Company's second-generation, cyclin-dependent kinase (CDK) 2/9 inhibitor as a targeted anti-cancer agent. The data showed that CYC065 inhibits key cancer and leukemia survival mechanisms and causes death by apoptosis in cancer cells. CYC065 is effective against acute myeloid leukemia (AML), and in particular, AML with genetic abnormalities such as MLL rearrangements (MLL-r), which confer a poor prognosis. CYC065 was also effective against uterine cancer cells including those resistant to chemotherapy and was especially potent in uterine cancer cells in which cyclin E, the partner protein of CDK2, was amplified or overexpressed. In each case CYC065 showed synergy with available anti-cancer agents. Results from preclinical studies by independent investigators on the Company's drug candidates sapacitabine and seliciclib, as well as CYC065, are also being presented. Preclinical data show that CYC065 may reverse drug resistance associated with addiction of cancer cells to cyclin E. CYC065 may also inhibit CDK9-dependent oncogenic and leukemogenic pathways, including malignancies driven by certain oncogenes and MLL-r. In their AACR presentation, Cyclacel scientists provided insights on the mechanism of action, determinants of sensitivity and synergistic combinations of CYC065 in AML. The pro-apoptotic mechanism of CYC065 included rapid inhibition of transcription. MLL gene status and levels of Bcl-2 family proteins correlated with sensitivity of AML cell lines to CYC065. Short pulse treatment was sufficient to inhibit sensitive AML cells. CYC065's potent anti-cancer activity was confirmed in AML xenograft models in which tumor growth inhibition ranging from 90 to 97% was achieved at well-tolerated dose levels. Combination studies revealed the potential to combine CYC065 with available and experimental leukemia therapies, including cytarabine. The potent in vitro and in vivo anti-cancer activity, opportunity for patient stratification and the ability to combine with anti-leukemic agents suggest that CYC065 may have therapeutic potential in AML.

Cyclacel Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Cyclacel Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of $299,000 against $247,000 a year ago. Operating loss was $3,974,000 against $5,782,000 a year ago. Loss from continuing operations before taxes was $4,026,000 against $5,907,000 a year ago. Net loss from continuing operations was $3,574,000 or $0.20 basic and diluted per share against $4,799,000 or $0.21 basic and diluted per share a year ago. Net loss was $3,559,000 or $0.20 basic and diluted per share against $4,799,000 or $0.21 basic and diluted per share a year ago. For the year, the company reported total revenues of $1,084,000 against $1,734,000 a year ago. Operating loss was $17,974,000 against $22,437,000 a year ago. Loss from continuing operations before taxes was $11,880,000 against $22,649,000 a year ago. Net loss from continuing operations was $10,210,000 or $1.29 basic and diluted per share against $19,406,000 or $0.89 basic and diluted per share a year ago. Net loss was $10,153,000 or $1.28 basic and diluted per share against $19,387,000 or $0.89 basic and diluted per share a year ago.

Cyclacel Pharmaceuticals, Inc. to Report Q4, 2014 Results on Mar 24, 2015

Cyclacel Pharmaceuticals, Inc. announced that they will report Q4, 2014 results at 4:30 PM, US Eastern Standard Time on Mar 24, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UXI1:GR €0.84 EUR -0.034

UXI1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for UXI1.
View Industry Companies
 

Industry Analysis

UXI1

Industry Average

Valuation UXI1 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.7x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYCLACEL PHARMACEUTICALS INC, please visit www.cyclacel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.